Editors' ChoiceGene Therapy Neutralizing antibodies for AAV vectors: The strange case of AAV5 Giuseppe RonzittiINTEGRARE, Genethon, INSERM, Univ. Evry, Université Paris-Saclay, 91002 Evry, France. Email: gronzitti{at}genethon.fr See allHide authors and affiliations Science Translational Medicine 19 Jun 2019:Vol. 11, Issue 497, eaax9567DOI: 10.1126/scitranslmed.aax9567 Giuseppe Ronzitti INTEGRARE, Genethon, INSERM, Univ. Evry, Université Paris-Saclay, 91002 Evry, France. Email: Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: gronzitti@genethon.fr Article Info & Metrics eLetters Article Information vol. 11 no. 497 DOI: https://doi.org/10.1126/scitranslmed.aax9567 Published By: American Association for the Advancement of Science Print ISSN: 1946-6234 Online ISSN: 1946-6242 History: . Copyright & Usage: Copyright © 2019, American Association for the Advancement of Science Author Information Giuseppe RonzittiINTEGRARE, Genethon, INSERM, Univ. Evry, Université Paris-Saclay, 91002 Evry, France. Email: gronzitti{at}genethon.fr Altmetric Article usage Article lifetimeLast 6 monthsThis monthArticle usage: June 2019 to March 2021 AbstractFullPdf Jun 2019180337517 Jul 2019103220 Aug 201971470 Sep 201951410 Oct 201991390 Nov 2019101081 Dec 201991120 Jan 20206980 Feb 2020101320 Mar 202010881 Apr 202051170 May 2020111300 Jun 202072114 Jul 2020111561 Aug 202041250 Sep 202091550 Oct 2020171160 Nov 202071130 Dec 202091060 Jan 20216711 Feb 202151103 Mar 20211150 View Full Text
Neutralizing antibodies for AAV vectors: The strange case of AAV5 By Giuseppe Ronzitti Science Translational Medicine19 Jun 2019 A clinical trial on hemophilia B demonstrated efficient liver targeting with AAV5 in the presence of neutralizing antibodies.
Neutralizing antibodies for AAV vectors: The strange case of AAV5 By Giuseppe Ronzitti Science Translational Medicine19 Jun 2019 A clinical trial on hemophilia B demonstrated efficient liver targeting with AAV5 in the presence of neutralizing antibodies.